Q-omics provides the consensus-scored TMEM170B profile across patient tissues and cancer cell-line models. TMEM170B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TMEM170B is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TMEM170B RNA expression shows 20,730 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, THCA, and THYM as cancer lineages where TMEM170B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM170B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM170B survival associations across molecular data types. TMEM170B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM170B RNA expression–survival associations across cancer types. High TMEM170B expression shows unfavorable associations in KICH and STAD, but favorable associations in LUAD, KIRC, PAAD and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TMEM170B RNA expression.
This table summarizes TMEM170B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM170B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM170B shows lower tumor expression in THCA, KICH, LUAD, LUSC, BRCA and BLCA. The THCA box plot shows higher TMEM170B RNA expression in normal versus tumor tissue (log2 FC = −1.254, t-test p < 0.001).
This table shows molecular features associated with TMEM170B in patient tissues and cancer cell lines. In patient samples, TMEM170B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM170B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
